The vitamin E-binding protein afamin increases in maternal serum during pregnancy  by Hubalek, Michael et al.
Clinica Chimica Acta 434 (2014) 41–47
Contents lists available at ScienceDirect
Clinica Chimica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /c l inch imThe vitamin E-binding protein afamin increases in maternal serum
during pregnancyMichael Hubalek a, Hannes Buchner b, Manfred G. Mörtl c, Dietmar Schlembach c,d, Berthold Huppertz e,
Branka Firulovic a, Wolfgang Köhler f, Erich Hafner g, Benjamin Dieplinger f, LudwigWildt h, Hans Dieplinger i,j,⁎
a Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria
b Institute of Medical Informatics, Biometry and Epidemiology, Medical School, Ludwig Maximilian University of Munich, Germany
c Department of Gynecology and Obstetrics, Medical University of Graz, Austria
d Department of Gynecology and Obstetrics, Jena University, Jena, Germany
e Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Austria
f Department of Laboratory Medicine, Konventhospital Barmherzige Brüder, Linz, Austria
g Department of Obstetrics and Gynecology, Danube Hospital/SMZ-Ost, Vienna, Austria
h Department of Gynecological Endocrinology and Reproductive Medicine, Innsbruck Medical University, Innsbruck, Austria
i Division of Genetic Epidemiology, Department of Medical Genetics, Clinical and Molecular Pharmacology, Innsbruck Medical University, Innsbruck, Austria
j Vitateq Biotechnology GmbH, Innsbruck, Austria⁎ Corresponding author at: Division of Genetic E
Medical Genetics, Molecular and Clinical Pharmacology,
Schoepfstrasse 41, A-6020 Innsbruck, Austria. Tel.: +43
900373570.
E-mail address: hans.dieplinger@i-med.ac.at (H. Diepl
http://dx.doi.org/10.1016/j.cca.2014.03.036
0009-8981/© 2014 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 5 February 2014
Received in revised form 21 March 2014
Accepted 26 March 2014
Available online 24 April 2014
Keywords:
Afamin in pregnancy
maternal expression
pregnancy complications
preeclampsia
Background: Afamin is a liver-derived plasma glycoprotein with vitamin E-binding properties and a putative
function in fertility. This study evaluated serum afamin concentrations during and postpartum to uncomplicated
pregnancies and investigated a potential association between afamin concentrations and pregnancy outcome.
Methods: Afamin serum concentrations were measured in women with uncomplicated pregnancies in a retro-
spective cohort (n = 466) at different gestational ages and a prospective observational study (n = 76) in the
ﬁrst, second and third trimester. Furthermore, afamin was determined in the ﬁrst trimester in a cross-sectional
pilot study including womenwith preeclampsia (PE), pregnancy-induced hypertension (PIH) and womenwith-
out pregnancy complications (n = 13 each). Finally, expression of afamin was investigated in human placental
tissue by RT-PCR and immunohistochemistry.
Results: Afamin concentrations increased linearly almost two-fold during pregnancy in both retrospective and
prospective studies in women without pregnancy complications with median afamin serum concentrations of
61.9 mg/l, 79.6 mg/l, and 98.6 mg/l in the ﬁrst, second, and third trimester, respectively. After delivery, median
afamin concentrations decreased to baseline values of 54.6 mg/l. In the pilot study with pregnancy complica-
tions, women with PE displayed signiﬁcantly higher median afamin concentrations than did women with un-
complicated pregnancy (70.0 mg/l vs. 55.4 mg/l, P = 0.007). Expression analyses revealed no placental afamin
expression at either mRNA or protein level in uncomplicated pregnancy.
Conclusion: A linear increase in the maternally expressed glycoprotein afamin during pregnancy may serve as
basic reference for subsequent investigations of afamin in pregnancy-related disorders.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Pregnancy is generally characterized by an increased generation
of reactive oxygen species (ROS). This is especially true for the pla-
centa, where mitochondrial activity and production of free superox-
ide radicals increase ROS quantity. It is typically accompanied by
reduced levels of antioxidants [1]. Imbalanced or poorly controlledpidemiology, Department of
Innsbruck Medical University,
512 900370570; fax: +43 512
inger).
. This is an open access article underoxidative stress related to dysregulated trophoblast development
may lead to pregnancy-associated complications, such as hypertensive
disorders or fetal growth restriction [2]. With their ability to stabilize
reactive free radicals, antioxidant vitamins act as the ﬁrst line of defense
against free radical attack and lipid peroxidation. Vitamin E is themajor
lipophilic antioxidant nutrient in the early stages of life from the time of
conception, during pregnancy and through the postnatal development
of the infant [3,4]. Mechanisms of its uptake by placenta and mammary
glandmost likely depend on lipoprotein receptors since most vitamin E
in human plasma is transported by lipoproteins.
The plasma glycoprotein afamin has been previously identiﬁed [5]
and described as an alternative carrier protein for vitamin E [6,7] in
extravascular ﬂuids, such as follicular ﬂuid, known for its reducedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Afamin belongs to the albumin gene family, is primarily expressed in
liver and is secreted into blood with subsequent distribution to the re-
spective extravascular ﬂuids [9].
In order to better understand the role of afamin in human fertilitywe
measured serum concentrations of afamin by ELISA [10] at various
gestational ages in women with uncomplicated pregnancies. Afamin
concentrations were correlated with those of recognized pregnancy
markers such as β-human chorionic gonadotrophin (hCG+β),
human placental lactogen (hPL) and free estriol. The marker proteins
hCG+β and hPL are synthesized by the human placenta while the
steroid estriol is a product of the materno-placento-fetal unit, thus
reﬂecting both feto-placental growth and development [11]. We then
evaluated the results of the retrospective study in a second, prospective
observational study in samples obtained at pre-speciﬁed time intervals
fromwomenwith uncomplicated pregnancies. Based on this systematic
study of afamin in uncomplicated pregnancy, afamin was ﬁnally also
measured in a pilot study of women diagnosedwith pregnancy compli-
cations, such as preeclampsia (PE) and pregnancy-induced hyperten-
sion (PIH), with the aim of determining the potential of afamin as an
early diagnostic or predictive marker for those conditions.
2. Materials and Methods
2.1. Subjects
The present multicenter study was performed by investigating
several cohorts with different study designs.
The ﬁrst, retrospective cohort study group comprised 466 consecu-
tive healthy pregnant women undergoing routine perinatal screening
between February and August 2006 at the Department of Gynecology
and Obstetrics of Innsbruck Medical University, Austria.
The second, prospective observational study group comprised 76
healthy pregnant women recruited between April 2007 and November
2008 at the Department of Gynecology and Obstetrics at the Medical
University of Graz, Austria. Three blood samples were taken at gesta-
tional weeks 12–13, 24–25 and 35–36, representing the ﬁrst, second
and third trimester of pregnancy, respectively. Blood was also collected
postpartum from 17 (22%) participants of this study group 43 ± 7 days
after delivery. At all times of blood collection, women in both study
groups were free of any pregnancy-associated complications. Only
women with uncomplicated singleton pregnancies carried to term
were eligible for study participation.
A third, cross-sectional study groupwas recruited at theDepartment
of Obstetrics and Gynecology, Danube Hospital/SMZ-Ost, Vienna,
Austria and comprised 13 women diagnosed with PE, 13 women with
PIH and 13 healthy pregnant women who served as controls. Women
with pregnancy complications and uncomplicated pregnancies
were matched for maternal and gestational age, gravidity and BMI;
their blood was obtained at the occasion of “ﬁrst trimester screen-
ing” between gestational weeks 11 and 14. Eight women with PE de-
livered their baby at gestational week ≥37, three at week b37 and
two at week b35. PE was deﬁned according to the classiﬁcation of
the International Society for the Study of Hypertension in Pregnancy
(ISSHP) [12].
All study participants were Caucasian. The studieswere approved by
the internal review boards and the ethics committees of the Medical
Universities of Innsbruck and Graz and the City of Vienna, in adherence
with theDeclaration of Helsinki; signed informed consent for participat-
ing in the study was obtained from all participants.
2.2. Analysis of parameters in serum samples
Blood was collected from all study participants after overnight
fasting and serum was obtained by low-speed centrifugation. Serum
aliquots were frozen and kept at−70 °C until analysis.Concentrations of afamin were measured with a previously
described double-antibody sandwich ELISA test, using a biotinylated
afﬁnity-puriﬁed polyclonal antibody for binding to streptavidin-
coated microtiter plates and the peroxidase-conjugated monoclonal
antibody N13 for detection. The intra-assay and inter-assay coefﬁ-
cients of variation were 3.3% and 6.2%, respectively, at a mean afamin
concentration of 73 mg/l [10].
Serum concentrations of free (unconjugated) estriol were measured
by competitive enzyme immunoassay; human placental lactogen
(hPL) was measured by sandwich ELISA (DRG Instruments, Marburg,
Germany). Human chorionic gonadotropin (hCG) was measured by
sandwich immunoassay on the Modular Analytics Platform E170
(Roche Diagnostics, Mannheim, Germany). This assay quantiﬁes
the intact hCG molecule plus the free β subunit of hCG and is there-
fore referred to as hCG+β.
2.3. Afamin tissue expression analysis
Term and pre-term placental tissues from women with uncom-
plicated pregnancies were obtained from the Department of Gyne-
cology and Obstetrics of the Medical University of Graz, Austria.
First-trimester placental tissue was obtained after induced pregnancy
termination for social, non-medical reasons.
Semi-quantitative RT-PCR was performed on RNA extracted from
human ﬁrst trimester and term placental tissue (n = 5 each) using
six different afamin primers [13], with 36 cycles, annealing temper-
ature 55 °C and 100 ng pooled total RNA applied for each reaction.
Human ribosomal protein L0 (RPL0) served as endogenous control.
Immunohistochemistry was performed on parafﬁn-embedded
formaldehyde-ﬁxed sections of human placental tissue (ﬁrst-trimes-
ter and term, n = 5 each) using two different afﬁnity-puriﬁed poly-
clonal anti-afamin antibodies (#2132 and #1055-4) raised in rabbits
in our laboratory after immunization with native afamin, puriﬁed
from human plasma [6]. Sections from human kidney known for
afamin expression (see www.proteinatlas.org) served as positive
controls, sections incubated without primary antibodies served as
negative controls.
2.4. Statistical analyses
Log base 2-transformed serum concentrations of afamin, free estriol,
hCG+β and hPL were compared across trimesters using ANalysis Of
VAriance (ANOVA). Spearman’s correlations between pairs of markers
were computed for each trimester and additionally, on the basis of de-
trended residuals, by subtracting the ordinary least squares ﬁtted
mean from all observations, and then averaging over a four-week mov-
ingwindowwith a stepwidth of oneweek. Normal linearmixedmodels
were used to model longitudinal trajectories of individual log base 2-
transformed concentrations of afamin separately for the retrospective
cohort and prospective observational studies according to gestational
age, accounting for within-patient correlation (random effects) and in-
ﬂuence of women’s age, parity, birth weight of the newborn (Ponderal
Index, PI), and body mass index (BMI) of the mother before onset of
pregnancy (ﬁxed effects). The Bayesian Information Criterion (BIC)
was used to select the optimal mean time trajectory, namely logarith-
mic or quadratic, and ﬁxed effects. All models contained random inter-
cepts; additional random effects, such as random slopes, were tested
using likelihood ratio tests.
Comparisons of afamin between women without and with preg-
nancy complications (i.e. PE and PIH) were performed with the
Wilcoxon test and the non-parametric Mann–Whitney U test, as ap-
propriate. Obtained p values were not adjusted for multiple compar-
isons and are therefore descriptive only.
All data were statistically analyzed with the SPSS 13.0 software
(SPSS Inc.), the R-2.14.2 package and the MedCalc 12.7.0.0 package
(MedCalc Software).
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3.1. Patient characteristics
Table 1 shows anthropometric characteristics of participating
pregnant women with uncomplicated pregnancies. Their age and
gestational age at delivery, pre-pregnancy BMI and Ponderal Index
(PI) of newborns were comparable. In the retrospective study group,
blood samples were acquired at different gestational ages; participants
from the prospective study group donated three samples at pre-
speciﬁed time points during pregnancy (see methods section).
3.2. Afamin in the retrospective study groupwith uncomplicated pregnancy
Median concentrations of afamin, free estriol, hPL and hCG+β
for each trimester of pregnancy for the retrospective cohort study
are listed in Table 2. Individual and population mean afamin curves
over the course of pregnancy indicate afamin changes during the
three trimesters of pregnancy (all P values b0.0001, Table 2,
Fig. 1A–D). Residual correlations after adjusting for the mean chang-
es over weeks of pregnancy between all markers were nearly negli-
gible: between afamin and free estriol, −0.01; afamin and hPL,
−0.09; afamin and hCG+β −0.03; free estriol and hPL, 0.37; free
estriol and hCG+β −0.20; hPL and hCG+β 0.07. However, when
evaluated separately for each trimester, afamin concentrations cor-
related signiﬁcantly with all three parameters in the second, but
not in the ﬁrst and third trimesters.
Unlike the other knownmarkers of pregnancy that exhibit nonlinear
trajectories over the course of pregnancy, afamin showed a consistent
linear increase during uncomplicated pregnancy with an average in-
crease of 2.17% (95% CI =2.03% to 2.31%) per week of pregnancy
resulting in an approximate-doubling of extrapolated average of afamin
values by the end of pregnancy (Fig. 1A). Speciﬁcally, the linear mixed
effects model for the log base 2-transformed afamin course contained
an intercept (estimate = 5.65, SE = 0.05, P b 0.0001) and slope for
week of pregnancy (estimate = 0.031, SE = 0.001, P b 0.0001). There
was signiﬁcant random variation of afamin concentrations, both at the
start and during the course of pregnancy (P b 0.0001).
In contrast to afamin, hCG+ β showed a sharp decline over the ﬁrst
20 weeks of pregnancy before reaching a plateau and slightly increasing
again towards delivery at term (Fig. 1B). There was signiﬁcant woman-
to-woman variability in the time course (P = 0.0003). Of all trans-
formations tested to describe the mean trajectory over weeks of
pregnancy, a model containing an intercept term (estimate =
20.13, SE = 0.25, P b 0.0001), slope for week (estimate = −0.51,Table 1
Participant characteristics at onset of uncomplicated pregnancy.
Characteristic
Age (yrs) Median
(25%, 75%-ile)
Range
Parity N (%) Nulliparous
Multiparous
Gestational age at delivery (weeks) Median
(25%, 75%-ile)
Range
BMI of women before pregnancy (kg/m2) Median
(25%, 75%-ile)
Range
PI of newborns (kg/m3) Median
(25%, 75%-ile)
Range
BMI, body mass index; PI, Ponderal Index.SE = 0.02, P b 0.0001), and a quadratic term for week (estimate =
0.009, SE = 0.0005, P b 0.0001) provided the best ﬁt.
Free estriol and hPL followed similar trajectories during the course of
pregnancy, steeply rising over the ﬁrst one to two trimesters and
continuing to rise gradually during the third trimester (Fig. 1C + D).
There was signiﬁcant woman-to-woman variability in the time course
for hPL (P b 0.0001) and free estriol (P b 0.0001). The mean trajectory
for free estriol was described by an intercept (estimate = −6.63,
SE = 0.25, P = b0.0001), and slope for the logarithm of time (esti-
mate = 3.77, SE = 0.08, P b 0.0001); for hPL the mean trajectory
was described by an intercept (estimate = −19.56, SE = 0.82,
P b 0.0001), slope for time (estimate = −0.17, SE = 0.02,
P b 0.0001), and slope for logarithm of time (estimate = 7.80,
SE = 0.39, P b 0.0001).
3.3. Afamin in the prospective study group with uncomplicated pregnancy
When comparing afamin concentrations in the prospective study of
76 women with uncomplicated pregnancies throughout pregnancy,
median afamin serum concentrations were 61.9 mg/l (25%, 75%-ile
54.8–69.2 mg/l) in the ﬁrst trimester, 79.6 mg/l (25%, 75%-ile
68.9–87.2 mg/l; Wilcoxon test, p b0.001 for comparison with afamin
in the ﬁrst trimester) in the second trimester, and 98.6 mg/l (25%,
75%-ile 89.1–107.5 mg/l; Wilcoxon test, p b0.001 for comparison with
afamin in the ﬁrst trimester; and Wilcoxon test, p b0.001 for compari-
son with afamin in the second trimester) in the third trimester of preg-
nancy (Fig. 2).
In 17womenwith afamin values available also after delivery, afamin
concentrations dropped to pre-pregnancy values (median 54.6 mg/l,
25%, 75%-ile 49.1-60.5 mg/l, range 41.8–70.6 mg/l).
3.4. Afamin in pregnancy complications
In the pilot cross-sectional study, ﬁrst-trimester median serum con-
centrations of afamin (25%, 75%-ile) in pregnant women suffering from
PE were found to be signiﬁcantly higher than in pregnant healthy con-
trols with the same gestational age (70.0 (68.0, 82.1) mg/l vs. 55.4
(50.8, 73.0) mg/l, P = 0.007). Women with PIH had intermediate
afamin concentrations of 69.8 (61.2, 75.8) mg/l, P = 0.07 (Fig. 3).
3.5. Expression analysis
Afamin expression was investigated in ﬁrst-trimester or term pla-
cental tissues at the mRNA and the protein level (Fig. 4A, B). No afamin
mRNA expression was observed whereas the positive control showed aRetrospective cohort study
(n = 466)
Prospective observational study
(n = 76)
28 32
(24, 32) (29, 35)
19, 44 19, 42
219 (47) 38 (50)
247 (53) 38 (50)
39 39
(38, 40) (39, 41)
25, 42 36, 42
23.5 21.2
(21.2, 27.1) (19.9, 23.4)
14.6, 55.5 17.8, 34.0
26.4 25.1
(25.0, 28.4) (24.1, 27.0)
17.1, 34.5 20.6, 31.4
Table 2
Biomarker characteristics by trimester of uncomplicated pregnancy (retrospective cohort study, n = 466, N = 659).
Biomarker First Trimester
(Weeks 1–12)
N = 120
Second Trimester
(Weeks 13–28)
N = 279
Third Trimester
(Weeks ≥29)
N = 260
P value
Afamin (mg/l) Median 65.1 87.8 103.6 b0.0001
(25%, 75%-ile) (52.5, 82.7) (73.4, 98.8) (93.0, 118.3)
Free estriol (ng/dl) Median 4.4 44.3 107.3 b0.0001
(25%, 75%-ile) (2.8, 6.1) (29.7, 65.6) (72.8, 156.8)
hPL (mg/l) Median 0.1 2.2 4.1 b0.0001
(25%, 75%-ile) (0.1, 0.2) (1.3, 2.8) (3.2, 5)
hCG+β (U/l) Median 74,429 9533 12,654 b0.0001
(25%, 75%-ile) (40,874, 98,989) (5309, 20,897) (5534, 22,284)
n denotes number of patients, N denotes number of samples investigated.
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was no staining signal found in placental tissue whereas kidney tissue
showed a clear positive staining.4. Discussion
This study demonstrates a nearly two-fold increase in serum con-
centrations of the vitamin E-binding protein afamin during the
course of uncomplicated pregnancy. The reason for steadily increas-
ing afamin concentrations in maternal blood during pregnancy is un-
clear. It is tempting to speculate that afamin rises during pregnancy
due to changing hormonal status and subsequent hormonal regulation
of the afamin gene expression inhuman liver. A comparablemechanism
has been reported for hormonal regulation (mostly estrogen-induced)Fig. 1. Serum concentrations of afamin and established pregnancy biomarkers during uncomp
overall means for A) afamin, B) hCG+β, C) free estriol, D) hPL.of hepatic synthesis of lipids and lipoproteins leading to physiological
hyperlipidemia during gestation [14].
In contrast to the steady linear increase in afamin throughout
pregnancy, time courses of hPL, hCG and free estriol followed non-
linear trajectories in accordance with earlier observations [15,16].
hCG+β and hPL are synthesized by the placenta, while estriol is a
product of the materno-placento-fetal unit, thus reﬂecting both
feto-placental growth and development [11].
Placental tissue expression experiments at both the mRNA and the
protein level revealed no placental expression of afamin suggesting a
maternal origin of increasing circulating afamin concentrations during
pregnancy. Theoretically, the increasing concentration of afamin during
pregnancy could also be due to embryonal and fetal expression of
afamin. However, reports about lacking expression of afamin (also
named “alpha-albumin”) in the fetal rat liver [17] and humanlicated pregnancy in a retrospective cohort study (n = 466). Trajectories are displayed by
Fig. 2. Afamin in a prospective study group with uncomplicated pregnancy (n= 76). Box
plots display median concentrations and bars indicating the 25% and 75%-ile of afamin
serum concentrations in the ﬁrst, second and third trimester of pregnancy at pre-
speciﬁed time points. Afamin concentrations were 61.9 mg/l in the ﬁrst trimester,
79.6 mg/l (Wilcoxon test, p b0.001 for comparison with afamin in the ﬁrst trimester) in
the second trimester, and 98.6 mg/l (Wilcoxon test, p b0.001 for comparison with afamin
in the ﬁrst trimester; andWilcoxon test, p b0.001 for comparison with afamin in the sec-
ond trimester)) in the third trimester of pregnancy.
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afamin expression and therefore most likely reﬂect a maternal origin
of increasing afamin concentrations during pregnancy. Interestingly,
this observation stands in clear contrast to established pregnancy-
related parameters, including estriol, hPL, hCG and adrenomedullin
that are all synthesized by the human placenta [11,19]. Adrenomedullin
is a vasorelaxing peptide involved in blood ﬂow regulation. Similar to
afamin, its plasma concentrations increase linearly during pregnancy
and correlate signiﬁcantlywith placental hormones, such as hPL [19,20].Fig. 3.Afamin concentrations in pregnancy complications (cross-sectional). Box plots
of afamin serum concentrations in ﬁrst trimester of pregnancy from healthy controls
(n = 13) and patients diagnosed with PIH (n = 13) and PE (n = 13). Median serum
concentrations of afamin in pregnant women suffering from PE were found to be sig-
niﬁcantly higher than in pregnant healthy controls with the same gestational age
(70.0 mg/l vs. 55.4 mg/l, P = 0.007). Women with PIH had intermediate afamin con-
centrations of 69.8 mg/l, P = 0.07.Women destined to develop hypertensive pregnancy complications
such as PE or PIH showed higher serum concentrations of afamin in the
ﬁrst trimester than did gestational age-matched healthy pregnant con-
trols. The difference between PE and healthy controls was signiﬁcant,
whereas PIH and controls differed only with borderline signiﬁcance,
possibly due to the small (pilot) study size. Further prospective studies
with substantially larger patient groups will be necessary to evaluate
afamin as potential earlymarker for PE and related pregnancy disorders.
Hypertensive disorders of pregnancy affect up to 8% of all gestations
and remain major causes of maternal and neonatal mortality and
morbidity worldwide [21]. Preeclampsia (PE) is a multisystem preg-
nancy disorder that complicates up to 3% of pregnancies depending
on the developmental stage of the respective world region [22–24].
The precise etiology is not fully understood; one undisputed origin
lies in the placenta. Impaired placental development leads to increased
tissue oxidative stress and placental apoptosis and necrosis, resulting in
the subsequent release of subcellular fragments causing a systemic
effect in the mother [25,26].
In PE, cytokines and ROS released from the mal-developed placenta
trigger a systemic inﬂammatory and oxidative state [27]. The maternal
endothelium as well as the placenta also overexpresses anti-
angiogenic factors that inhibit the normal function of pregnancy-
related pro-angiogenic factors. The combination of these factors is
believed to underlie a systemic endothelial dysfunction that is consis-
tently found in the mother during symptomatic PE. Likewise, metabolic
complications including insulin resistance, coagulation defects and hy-
perlipidemia contribute to an increased risk for cardiovascular diseases.
Therefore, PE and related pregnancy complications have been previous-
ly discussed as the “metabolic syndrome of pregnancy” [28]. Although
reversible after delivery, women suffering from such pregnancy disor-
ders carry increased additive risks for future cardiovascular diseases.
Our ﬁndings raise the possibility of associations between afamin and
components of the metabolic syndrome also in the general population.
Despite intensive research, risk estimation for developing PE prior to
the onset of symptoms did not improve signiﬁcantly until very recently
[29]. As previously reviewed [30], the heterogeneous nature of PE calls
for a combination of independent biomarkers, each representing a path-
ophysiological process, to provide suitable early diagnostic power for
predicting PE. Such markers would contribute substantially to identify-
ing high-risk women in need of closer supervision in secondary care.
Additionally, there is now evidence from a recent meta-analysis that
the prophylactic use of low-dose aspirin may reduce the incidence of
PE by about 50%, provided that treatment starts before the 16th week
of pregnancy [31]. These ﬁndings highly reinforce the need for early
identiﬁcation of women at risk for developing PE during pregnancy
with the objective of implementing therapeutic interventions to im-
prove perinatal and maternal outcome. Indeed, very recent screening
studies of ﬁrst-trimester samples of large cohorts of uncomplicated
and pathological pregnancies revealed detection rates for developing
early and late PE of 90% and 60%, respectively, when maternal factors,
biophysical and biochemical markers were combined [23,32]. Biochem-
ical plasmamarkers, thought to be involved in placentation, include sol-
uble endoglin, placental protein 13 (PP-13) [33] and pregnancy-
associated plasma protein A (PAPP-A). Although these very recent
substantial achievements have led to promising ﬁrst-trimester risk
assessments for developing PE, further large clinical studies including
additional biomarkers are needed to translate the current marker
panel into routine clinical practice.
The physiological function of afamin is largely unknown. Although
reduced afamin plasma concentrations have been described in patients
diagnosedwith ovarian cancer, the evidence for a causal relation is lack-
ing [34,35]. The previously reported abundance of afamin in human fol-
licle ﬂuid suggests the importance of afamin for oocyte development,
maturation and hence fertility in general, most likely due to its vitamin
E-carrying property [6]. Recently, afamin was identiﬁed as a potential
biomarker for trisomy 21 by proteomic comparative analysis of plasma
Fig. 4. Afamin expression in human placenta. Expression analysis of afamin in human ﬁrst-trimester and term placenta (n = 5, each). A, RT-PCR of RNA extracted from placental tissue;
used primers are described in inserted table [13]. B, immunohistochemistry of human placental tissue using two different polyclonal anti-afamin antibodies (anti-afamin 1, 2). Sections
from human kidney served as positive controls, sections incubated without primary antibodies as negative controls. Arrowheads point to glomerulus. Magniﬁcation 360x.
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a later study comparing 25 women pregnant with trisomy-affected
babies and 50 euploid healthy pregnancies [36].
In conclusion, ﬁndings of a linear, nearly two-fold increase in the
maternally expressed glycoprotein afamin during pregnancy have
been used as basic reference for subsequent investigations of afamin
in pregnancy-related disorders and suggest a potential for afamin to
serve as a predictive marker for such conditions. However, further
prospectively planned and adequately powered studies are needed
to conﬁrm the potential role of afamin as marker for pregnancy
complications.
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